Healthcare professionals with years of experience successfully treating patients with IC offer valuable insights in the comprehensive “best practices” articles you can access below.
NP Best Practices
This article offers nurse practitioners a wealth of information about effective diagnosis and treatment of IC.
Download PDF
Download PDF
IC Best Practices
Healthcare professionals from gynecology and urology practices who routinely see patients with IC—referred to as IC treaters—have developed some practical approaches to the diagnosis and treatment of IC.
Download PDF
Download PDF
Important Safety Information
- Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients
- Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage
- Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp
- Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug
- Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%)